Originally approved for treating PIK3CA-mutated, hormone receptor-positive advanced breast cancer [9] and overgrowth syndromes [10], alpelisib has also shown efficacy in managing non-islet cell tumor hypoglycemia [11]. This evidence concerns the gene NR4A1 and overgrowth syndrome.